---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-05-02T22:51:11.157632'
end_time: '2026-05-02T22:59:17.312041'
duration_seconds: 486.15
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: AKT1
  gene_symbol: AKT1
  uniprot_accession: P31749
  protein_description: 'RecName: Full=RAC-alpha serine/threonine-protein kinase; EC=2.7.11.1
    {ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:29343641,
    ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; AltName: Full=Protein
    kinase B; Short=PKB; AltName: Full=Protein kinase B alpha; Short=PKB alpha; AltName:
    Full=Proto-oncogene c-Akt; AltName: Full=RAC-PK-alpha;'
  gene_info: Name=AKT1 {ECO:0000312|HGNC:HGNC:391}; Synonyms=PKB, RAC;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the protein kinase superfamily. AGC Ser/Thr
  protein_domains: AGC-kinase_C. (IPR000961); Akt1. (IPR034676); Kinase-like_dom_sf.
    (IPR011009); PH-like_dom_sf. (IPR011993); PH_domain. (IPR001849)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 18
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P31749
- **Protein Description:** RecName: Full=RAC-alpha serine/threonine-protein kinase; EC=2.7.11.1 {ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; AltName: Full=Protein kinase B; Short=PKB; AltName: Full=Protein kinase B alpha; Short=PKB alpha; AltName: Full=Proto-oncogene c-Akt; AltName: Full=RAC-PK-alpha;
- **Gene Information:** Name=AKT1 {ECO:0000312|HGNC:HGNC:391}; Synonyms=PKB, RAC;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the protein kinase superfamily. AGC Ser/Thr
- **Key Domains:** AGC-kinase_C. (IPR000961); Akt1. (IPR034676); Kinase-like_dom_sf. (IPR011009); PH-like_dom_sf. (IPR011993); PH_domain. (IPR001849)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AKT1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AKT1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AKT1** (gene ID: AKT1, UniProt: P31749) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P31749
- **Protein Description:** RecName: Full=RAC-alpha serine/threonine-protein kinase; EC=2.7.11.1 {ECO:0000269|PubMed:12172553, ECO:0000269|PubMed:15861136, ECO:0000269|PubMed:29343641, ECO:0000269|PubMed:32322062, ECO:0000269|PubMed:33594058}; AltName: Full=Protein kinase B; Short=PKB; AltName: Full=Protein kinase B alpha; Short=PKB alpha; AltName: Full=Proto-oncogene c-Akt; AltName: Full=RAC-PK-alpha;
- **Gene Information:** Name=AKT1 {ECO:0000312|HGNC:HGNC:391}; Synonyms=PKB, RAC;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the protein kinase superfamily. AGC Ser/Thr
- **Key Domains:** AGC-kinase_C. (IPR000961); Akt1. (IPR034676); Kinase-like_dom_sf. (IPR011009); PH-like_dom_sf. (IPR011993); PH_domain. (IPR001849)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AKT1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AKT1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AKT1** (gene ID: AKT1, UniProt: P31749) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

# Comprehensive Research Report: Human **AKT1** (UniProt **P31749**) — Functional Annotation, Biology, and Recent Translational Progress

## 0. Gene/Protein identity verification (mandatory)
The UniProt accession **P31749** corresponds to **human AKT1** (also known as **protein kinase B alpha; PKBα; RAC-alpha serine/threonine-protein kinase**), a core serine/threonine kinase in the **PI3K–AKT–mTOR** signaling axis. Recent sources explicitly describe AKT as “protein kinase B (PKB)” with three isoforms (AKT1/2/3) and place AKT1 in this pathway context. (zhong2024selectivitystudiesand pages 1-3, kumar2024identificationofpotential pages 1-2)

The retrieved literature describing AKT1 consistently matches the UniProt-provided family/domain expectations: an **N-terminal PH domain**, a **central kinase domain**, and a **C-terminal AGC regulatory region/tail**. (zhong2024selectivitystudiesand pages 1-3, kumar2024identificationofpotential pages 1-2)

## 1. Key concepts and definitions (current understanding)

### 1.1 Core biochemical function (what AKT1 “does”)
AKT1 is a **serine/threonine protein kinase** (PKB) that is activated downstream of receptor tyrosine kinases (RTKs), GPCRs, and insulin receptor substrates (IRS) via PI3K lipid signaling. (kumar2024identificationofpotential pages 1-2, zhong2024selectivitystudiesand pages 1-3)

While several retrieved sources emphasize regulation by the ATP-binding pocket and ATP-competitive inhibitors rather than writing the catalytic reaction explicitly, they directly frame AKT1 as a kinase whose activity is controlled by phosphorylation at **Thr308** (activation loop) and **Ser473** (hydrophobic motif), consistent with canonical AGC-family kinase biochemistry. (brandherm2024strukturbasiertesdesignsynthese pages 28-32, kumar2024identificationofpotential pages 1-2)

### 1.2 Domain architecture and key structural determinants
**Domain organization (AKT1)**:
- **Pleckstrin homology (PH) domain** at the N-terminus
- **Catalytic kinase domain** (central)
- **C-terminal AGC regulatory region/tail** (hydrophobic-motif-containing) (zhong2024selectivitystudiesand pages 1-3, kumar2024identificationofpotential pages 1-2)

One 2024 study reports approximate boundaries for AKT1: **PH (5–108), kinase (150–408), AGC C-terminal region (409–480)**. (Kumar et al., 2024-07, *Molecular Diversity*, https://doi.org/10.1007/s11030-023-10671-1) (kumar2024identificationofpotential pages 1-2)

**PH-domain lipid binding concept**: the PH domain binds **PtdIns(3,4,5)P3 (PIP3)** (and can also engage **PtdIns(3,4)P2**), creating a basic binding pocket; lipid binding perturbs an ionic/hydrogen-bond network involving residues such as **Lys14, Glu17, Asn53, Arg86**. (kumar2024identificationofpotential pages 1-2)

### 1.3 Activation mechanism (canonical PI3K→PIP3→AKT1)
Across recent sources, the activation model is consistent:
1) Ligand stimulation activates **PI3K**, which converts membrane phosphoinositides (PIP2→PIP3). (kumar2024identificationofpotential pages 1-2)
2) **PIP3 binds AKT1’s PH domain**, recruiting AKT1 to membranes and triggering a conformational change that enables phosphorylation. (kumar2024identificationofpotential pages 1-2, zhong2024selectivitystudiesand pages 1-3)
3) **PDK1 phosphorylates AKT1 at Thr308** (activation loop), and **mTORC2 phosphorylates Ser473** (hydrophobic motif) for full activation. (kumar2024identificationofpotential pages 1-2)

A 2024 review similarly describes PIP3 binding exposing an activation-loop residue referred to as **Thr309** (nomenclature discrepancy vs the commonly cited Thr308) and notes subsequent phosphorylation at **Ser473** by **mTORC2**, underscoring the same biochemical logic: PIP3-dependent membrane recruitment precedes sequential phosphorylation events. (Zhong & Goodwin, 2024-03, *Molecules*, https://doi.org/10.3390/molecules29061233) (zhong2024selectivitystudiesand pages 1-3)

### 1.4 Substrate network and pathway position (what AKT1 regulates)
AKT is described as phosphorylating **>100 substrates**, linking it to **protein biosynthesis, proliferation, survival, migration, and glucose metabolism**. (brandherm2024strukturbasiertesdesignsynthese pages 28-32)

Representative canonical downstream substrates/effectors explicitly listed in the 2024 sources include:
- **TSC2 / TSC complex** (inhibition promotes mTORC1 signaling) (brandherm2024strukturbasiertesdesignsynthese pages 262-264, brandherm2024strukturbasiertesdesignsynthese pages 28-32)
- **PRAS40 (AKT1S1)**, described as an insulin-regulated inhibitor of mTORC1 (phosphorylation contributes to mTORC1 activation) (brandherm2024strukturbasiertesdesignsynthese pages 262-264, brandherm2024strukturbasiertesdesignsynthese pages 28-32)
- **FOXO/Forkhead box O1** transcription factors (AKT phosphorylation inhibits FOXO signaling, shifting toward survival/growth programs) (brandherm2024strukturbasiertesdesignsynthese pages 262-264, brandherm2024strukturbasiertesdesignsynthese pages 28-32)
- **BAD** (AKT phosphorylation contributes to BAD inactivation and survival signaling) (brandherm2024strukturbasiertesdesignsynthese pages 262-264, brandherm2024strukturbasiertesdesignsynthese pages 28-32)
- **GSK-3 (GSK3β)** (AKT phosphorylation inhibits GSK3; a canonical substrate also supported by structural/substrate literature referenced in 2024 sources) (brandherm2024strukturbasiertesdesignsynthese pages 28-32, brandherm2024strukturbasiertesdesignsynthese pages 260-262)

## 2. Recent developments and latest research (prioritizing 2023–2024)

### 2.1 2024 mechanistic refinements: PH-domain conformational control and autoinhibition concepts
Recent 2024 work synthesizes a view that AKT-family kinases occupy **autoinhibited conformations** in which the **PH domain interacts with the kinase domain**, and that activation involves conformational release coupled to membrane engagement by PIP3. (xu2024capturingautoinhibitedpdk1 pages 1-2, kumar2024identificationofpotential pages 1-2)

In addition, 2024 sources emphasize that the **PH-domain conformational state** (PH-in vs PH-out) is coupled to opening of the kinase/ATP-binding region and exposure of the activation loop for phosphorylation by PDK1, with mTORC2 phosphorylation following. (brandherm2024strukturbasiertesdesignsynthese pages 28-32)

### 2.2 2024 drug discovery directions: isoform selectivity, allostery, and covalency
A 2024 inhibitors-focused review highlights a practical medicinal chemistry issue: **cutaneous toxicity (rash)** has been linked to **AKT2 inhibition**, motivating **AKT1-selective** inhibitor design strategies. (zhong2024selectivitystudiesand pages 1-3)

The same 2024 review classifies AKT inhibitors into **ATP-competitive inhibitors** (e.g., capivasertib, ipatasertib) and **allosteric/covalent** inhibitors (e.g., MK-2206; covalent allosteric approaches), and discusses mutation-associated resistance differences between inhibitor classes. (zhong2024selectivitystudiesand pages 1-3)

### 2.3 2023–2024 cancer genomics perspective (AKT alterations)
A 2024 review estimates that **AKT1–3 mutations occur in ~3–5% of cancers**, placing AKT alterations among recurrent but not ubiquitous oncogenic events. (zhong2024selectivitystudiesand pages 1-3)

## 3. Current applications and real-world implementations

### 3.1 Precision oncology: AKT inhibition in endocrine-resistant breast cancer
A major real-world implementation of AKT pathway targeting is the **phase III CAPItello-291 trial** (published 2023-06) testing **capivasertib (AKT inhibitor) + fulvestrant** in **hormone receptor-positive, HER2-negative advanced breast cancer** after progression on aromatase inhibitor therapy (with or without prior CDK4/6 inhibitor). (Turner et al., 2023-06, *NEJM*, https://doi.org/10.1056/NEJMoa2214131) (zhong2024selectivitystudiesand pages 1-3)

This trial explicitly uses an “AKT pathway-altered” subgroup defined by **PIK3CA, AKT1, or PTEN** alterations, exemplifying how AKT1 biology informs stratification strategies. (zhong2024selectivitystudiesand pages 1-3)

### 3.2 Clinical trial ecosystem (evidence of ongoing implementation)
ClinicalTrials.gov records demonstrate continuing development and optimization of AKT inhibition, including:
- **Capivasertib** studies in breast cancer “real world practice” settings (e.g., phase IIIB) and large prostate cancer studies (phase III). (clinical trial records retrieved; not cited here because the current evidence snippets were not extracted into citable context IDs)

## 4. Expert opinions and analysis (authoritative synthesis)

### 4.1 Why AKT1 is a central node but challenging drug target
Recent 2024 analyses frame AKT as a **central effector** connecting membrane lipid signals to broad cellular outcomes via a large substrate set (“>100 substrates”), which explains both therapeutic potential and toxicity liabilities from pathway-wide metabolic effects. (brandherm2024strukturbasiertesdesignsynthese pages 28-32)

### 4.2 Why isoform selectivity matters
The 2024 inhibitor review argues that adverse effects (notably **cutaneous toxicity**) are linked to inhibition of **AKT2**, reinforcing the expert consensus that **isoform-selective AKT1/AKT3 targeting** or pathway-context-dependent targeting may improve therapeutic index. (zhong2024selectivitystudiesand pages 1-3)

## 5. Recent statistics and quantitative data (from recent studies)

### 5.1 CAPItello-291 efficacy and biomarker prevalence (2023-06)
In CAPItello-291 (N=708 randomized), **40.8%** of participants had **AKT pathway alterations** (PIK3CA/AKT1/PTEN). (zhong2024selectivitystudiesand pages 1-3)

Progression-free survival (investigator-assessed):
- **Overall population**: median **7.2 months** (capivasertib–fulvestrant) vs **3.6 months** (placebo–fulvestrant); **HR 0.60** (95% CI 0.51–0.71). (zhong2024selectivitystudiesand pages 1-3)
- **AKT pathway-altered population**: median **7.3 months** vs **3.1 months**; **HR 0.50** (95% CI 0.38–0.65). (zhong2024selectivitystudiesand pages 1-3)

Key grade ≥3 adverse events:
- Rash: **12.1%** vs **0.3%**
- Diarrhea: **9.3%** vs **0.3%**
- Discontinuation due to AEs: **13.0%** vs **2.3%** (zhong2024selectivitystudiesand pages 1-3)

### 5.2 Pan-cancer mutation prevalence estimate (2024-03)
A 2024 review reports AKT1–3 mutations in approximately **3–5% of cancers**. (zhong2024selectivitystudiesand pages 1-3)

## Summary table (quick reference)
The following table consolidates identity, activation, canonical substrates, and a key 2023 clinical implementation with quantitative outcomes.

| Category | Item | Key details | Quantitative data | Source / year |
|---|---|---|---|---|
| Identity / verification | AKT1 (human) | UniProt P31749 corresponds to human RAC-alpha serine/threonine-protein kinase / protein kinase B alpha (PKBα), one of three AKT isoforms in the PI3K/AKT/mTOR pathway (zhong2024selectivitystudiesand pages 1-3, kumar2024identificationofpotential pages 1-2) | — | UniProt P31749; supported by 2024 reviews/articles (zhong2024selectivitystudiesand pages 1-3, kumar2024identificationofpotential pages 1-2) |
| Domain organization | PH domain, kinase domain, C-terminal regulatory tail | AKT1 contains an N-terminal pleckstrin homology (PH) domain, a central catalytic kinase domain, and a C-terminal AGC regulatory region; one 2024 source gives boundaries PH 5–108, kinase 150–408, AGC tail 409–480 (zhong2024selectivitystudiesand pages 1-3, kumar2024identificationofpotential pages 1-2) | Domain boundaries: PH 5–108; kinase 150–408; tail 409–480 (kumar2024identificationofpotential pages 1-2) | Kumar et al., 2024, *Molecular Diversity*, doi:10.1007/s11030-023-10671-1, https://doi.org/10.1007/s11030-023-10671-1 (kumar2024identificationofpotential pages 1-2) |
| Activation mechanism | PIP3 / PH-domain recruitment | PI3K-generated PIP3 binds the AKT1 PH domain, driving membrane recruitment and conformational change that exposes the activation loop for phosphorylation; PDK1 phosphorylates Thr308/Thr309 and mTORC2 phosphorylates Ser473 for full activation (zhong2024selectivitystudiesand pages 1-3, kumar2024identificationofpotential pages 1-2, xu2024capturingautoinhibitedpdk1 pages 1-2) | PH-domain lipid-binding residues undergo reported positional shifts on ligand binding: Arg86 2.3 Å, Lys14 1.2 Å, Arg23 6.2 Å (kumar2024identificationofpotential pages 1-2) | Zhong & Goodwin, 2024, *Molecules*, doi:10.3390/molecules29061233, https://doi.org/10.3390/molecules29061233; Kumar et al., 2024, https://doi.org/10.1007/s11030-023-10671-1 (zhong2024selectivitystudiesand pages 1-3, kumar2024identificationofpotential pages 1-2) |
| Activation phosphosites | Thr308/Thr309 and Ser473 | Recent sources describe activation-loop phosphorylation at Thr308/Thr309 by PDK1 and hydrophobic-motif phosphorylation at Ser473 by mTORC2; older nomenclature in one 2024 review lists Thr309 for AKT1, but the canonical human AKT1 activation-loop residue is widely referred to as Thr308 (zhong2024selectivitystudiesand pages 1-3, kumar2024identificationofpotential pages 1-2) | Two essential activating phosphosites highlighted (zhong2024selectivitystudiesand pages 1-3, kumar2024identificationofpotential pages 1-2) | Zhong & Goodwin, 2024, https://doi.org/10.3390/molecules29061233; Kumar et al., 2024, https://doi.org/10.1007/s11030-023-10671-1 (zhong2024selectivitystudiesand pages 1-3, kumar2024identificationofpotential pages 1-2) |
| Localization | Cytosol to membrane-associated active state | AKT1 is autoinhibited in the cytosol and becomes activated upon PH-domain engagement with phosphoinositides at membranes; structural work cited in 2024 sources supports PH–kinase domain autoinhibition and membrane-accessible active conformations (kumar2024identificationofpotential pages 1-2, xu2024capturingautoinhibitedpdk1 pages 1-2) | — | Kumar et al., 2024, https://doi.org/10.1007/s11030-023-10671-1; Xu et al., 2024, doi:10.1021/acs.jcim.4c01392, https://doi.org/10.1021/acs.jcim.4c01392 (kumar2024identificationofpotential pages 1-2, xu2024capturingautoinhibitedpdk1 pages 1-2) |
| Canonical substrate / process | GSK3β | AKT phosphorylates and inhibits GSK3β, promoting anabolic/growth signaling and glycogen/protein synthesis programs (kumar2024identificationofpotential pages 1-2, brandherm2024strukturbasiertesdesignsynthese pages 260-262) | — | Kumar et al., 2024; structural/substrate support cited in 2024 thesis review (kumar2024identificationofpotential pages 1-2, brandherm2024strukturbasiertesdesignsynthese pages 260-262) |
| Canonical substrate / process | BAD | AKT phosphorylates BAD, promoting its inactivation and favoring cell survival/anti-apoptotic signaling (brandherm2024strukturbasiertesdesignsynthese pages 262-264, kumar2024identificationofpotential pages 1-2) | — | Brandherm, 2024 compilation citing canonical BAD studies; Kumar et al., 2024 (brandherm2024strukturbasiertesdesignsynthese pages 262-264, kumar2024identificationofpotential pages 1-2) |
| Canonical substrate / process | FOXO transcription factors | AKT phosphorylates FOXO/Forkhead transcription factors, inhibiting their transcriptional activity and thereby suppressing pro-apoptotic/stress-response gene expression (brandherm2024strukturbasiertesdesignsynthese pages 262-264, kumar2024identificationofpotential pages 1-2) | — | Brandherm, 2024 compilation; Kumar et al., 2024 (brandherm2024strukturbasiertesdesignsynthese pages 262-264, kumar2024identificationofpotential pages 1-2) |
| Canonical substrate / process | TSC2 | AKT phosphorylates and inhibits TSC2, relieving repression of mTORC1 signaling and promoting growth-related translation/metabolism (brandherm2024strukturbasiertesdesignsynthese pages 262-264) | — | Brandherm, 2024 compilation citing TSC2-AKT literature (brandherm2024strukturbasiertesdesignsynthese pages 262-264) |
| Canonical substrate / process | PRAS40 / AKT1S1 | AKT phosphorylates PRAS40 (AKT1S1), an insulin-regulated inhibitor of mTORC1; phosphorylation contributes to mTORC1 activation (brandherm2024strukturbasiertesdesignsynthese pages 262-264) | — | Brandherm, 2024 compilation citing PRAS40 literature (brandherm2024strukturbasiertesdesignsynthese pages 262-264) |
| Clinical application (2023) | Capivasertib + fulvestrant, CAPItello-291 | Phase III trial in HR-positive, HER2-negative advanced breast cancer after aromatase inhibitor therapy ± prior CDK4/6 inhibitor; dual primary endpoint included overall population and AKT-pathway-altered tumors (PIK3CA, AKT1, PTEN) (zhong2024selectivitystudiesand pages 1-3) | n=708 randomized; 40.8% had AKT-pathway alterations; 69.1% had prior CDK4/6 inhibitor for advanced disease (zhong2024selectivitystudiesand pages 1-3) | Turner et al., 2023, *N Engl J Med*, doi:10.1056/NEJMoa2214131, https://doi.org/10.1056/NEJMoa2214131 (zhong2024selectivitystudiesand pages 1-3) |
| Clinical outcome (2023) | Progression-free survival benefit | Capivasertib plus fulvestrant improved investigator-assessed PFS versus placebo plus fulvestrant in both the overall and pathway-altered populations (zhong2024selectivitystudiesand pages 1-3) | Overall population: median PFS 7.2 vs 3.6 months; HR 0.60 (95% CI 0.51–0.71). AKT-pathway-altered population: 7.3 vs 3.1 months; HR 0.50 (95% CI 0.38–0.65) (zhong2024selectivitystudiesand pages 1-3) | Turner et al., 2023, https://doi.org/10.1056/NEJMoa2214131 (zhong2024selectivitystudiesand pages 1-3) |
| Safety / implementation | Key grade ≥3 adverse events with capivasertib | Most frequent grade ≥3 toxicities were rash and diarrhea; AKT2 inhibition has been linked in 2024 review literature to cutaneous toxicity, motivating isoform-selective inhibitor design (zhong2024selectivitystudiesand pages 1-3, brandherm2024strukturbasiertesdesignsynthese pages 264-266) | Grade ≥3 rash 12.1% vs 0.3%; grade ≥3 diarrhea 9.3% vs 0.3%; discontinuation 13.0% vs 2.3% (zhong2024selectivitystudiesand pages 1-3) | Turner et al., 2023, https://doi.org/10.1056/NEJMoa2214131; Zhong & Goodwin, 2024, https://doi.org/10.3390/molecules29061233 (zhong2024selectivitystudiesand pages 1-3, brandherm2024strukturbasiertesdesignsynthese pages 264-266) |


*Table: This table condenses verified identity, activation biology, canonical substrates, and a recent clinical implementation example for human AKT1. It is useful as a quick reference linking core molecular function to 2023–2024 translational evidence.*

## Limitations of the current evidence set
- Within the retrieved 2023–2024 texts, the catalytic reaction is consistently framed as “serine/threonine kinase” activity and phosphorylation-site regulation, but an explicit sentence stating “transfer of phosphate from ATP to protein Ser/Thr residues” was not present in the extracted evidence snippets; the mechanistic context (ATP pocket; phosphorylation of substrates) is nevertheless strongly supported. (brandherm2024strukturbasiertesdesignsynthese pages 28-32, kumar2024identificationofpotential pages 1-2)
- Attempts to retrieve a pathway schematic figure for AKT activation from the retrieved PDFs did not yield an AKT activation diagram; the available figures were primarily inhibitor chemical structures, docking panels, or clinical Kaplan–Meier plots.

## Key cited sources (with dates and URLs)
- Zhong HA, Goodwin DT. **Selectivity Studies and Free Energy Calculations of AKT Inhibitors**. *Molecules*. **2024-03**. https://doi.org/10.3390/molecules29061233 (zhong2024selectivitystudiesand pages 1-3)
- Kumar HB et al. **Identification of potential Akt activators: a ligand and structure-based computational approach**. *Molecular Diversity*. **2024-07**. https://doi.org/10.1007/s11030-023-10671-1 (kumar2024identificationofpotential pages 1-2)
- Turner NC et al. **Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer** (CAPItello-291). *N Engl J Med*. **2023-06**. https://doi.org/10.1056/NEJMoa2214131 (zhong2024selectivitystudiesand pages 1-3)
- Xu L, Jang H, Nussinov R. **Capturing Autoinhibited PDK1 Reveals the Linker’s Regulatory Role…** *J Chem Inf Model*. **2024-09**. https://doi.org/10.1021/acs.jcim.4c01392 (xu2024capturingautoinhibitedpdk1 pages 1-2)
- Brandherm S. **Struktur-basiertes Design… zur kovalent-allosterischen Adressierung der Proteinkinase Akt**. TU Dortmund. **2024-01**. https://doi.org/10.17877/de290r-24470 (brandherm2024strukturbasiertesdesignsynthese pages 262-264, brandherm2024strukturbasiertesdesignsynthese pages 28-32)


References

1. (zhong2024selectivitystudiesand pages 1-3): Haizhen A. Zhong and David T. Goodwin. Selectivity studies and free energy calculations of akt inhibitors. Molecules, 29:1233, Mar 2024. URL: https://doi.org/10.3390/molecules29061233, doi:10.3390/molecules29061233. This article has 13 citations.

2. (kumar2024identificationofpotential pages 1-2): Harish B. Kumar, Suman Manandhar, Ekta Rathi, Shama Prasada Kabekkodu, Chetan Hasmukh Mehta, Usha Yogendra Nayak, Suvarna G. Kini, and K. Sreedhara Ranganath Pai. Identification of potential akt activators: a ligand and structure-based computational approach. Molecular Diversity, 28:1485-1503, Jul 2024. URL: https://doi.org/10.1007/s11030-023-10671-1, doi:10.1007/s11030-023-10671-1. This article has 16 citations and is from a peer-reviewed journal.

3. (brandherm2024strukturbasiertesdesignsynthese pages 28-32): Sven Brandherm. Struktur-basiertes design, synthese und charakterisierung von wirkstoffen zur kovalent-allosterischen adressierung der proteinkinase akt. Text, Jan 2024. URL: https://doi.org/10.17877/de290r-24470, doi:10.17877/de290r-24470. This article has 0 citations and is from a peer-reviewed journal.

4. (brandherm2024strukturbasiertesdesignsynthese pages 262-264): Sven Brandherm. Struktur-basiertes design, synthese und charakterisierung von wirkstoffen zur kovalent-allosterischen adressierung der proteinkinase akt. Text, Jan 2024. URL: https://doi.org/10.17877/de290r-24470, doi:10.17877/de290r-24470. This article has 0 citations and is from a peer-reviewed journal.

5. (brandherm2024strukturbasiertesdesignsynthese pages 260-262): Sven Brandherm. Struktur-basiertes design, synthese und charakterisierung von wirkstoffen zur kovalent-allosterischen adressierung der proteinkinase akt. Text, Jan 2024. URL: https://doi.org/10.17877/de290r-24470, doi:10.17877/de290r-24470. This article has 0 citations and is from a peer-reviewed journal.

6. (xu2024capturingautoinhibitedpdk1 pages 1-2): Liang Xu, Hyunbum Jang, and Ruth Nussinov. Capturing autoinhibited pdk1 reveals the linker’s regulatory role, informing innovative inhibitor design. Journal of Chemical Information and Modeling, 64:7709-7724, Sep 2024. URL: https://doi.org/10.1021/acs.jcim.4c01392, doi:10.1021/acs.jcim.4c01392. This article has 11 citations and is from a peer-reviewed journal.

7. (brandherm2024strukturbasiertesdesignsynthese pages 264-266): Sven Brandherm. Struktur-basiertes design, synthese und charakterisierung von wirkstoffen zur kovalent-allosterischen adressierung der proteinkinase akt. Text, Jan 2024. URL: https://doi.org/10.17877/de290r-24470, doi:10.17877/de290r-24470. This article has 0 citations and is from a peer-reviewed journal.

## Citations

1. kumar2024identificationofpotential pages 1-2
2. zhong2024selectivitystudiesand pages 1-3
3. brandherm2024strukturbasiertesdesignsynthese pages 28-32
4. brandherm2024strukturbasiertesdesignsynthese pages 262-264
5. brandherm2024strukturbasiertesdesignsynthese pages 260-262
6. brandherm2024strukturbasiertesdesignsynthese pages 264-266
7. https://doi.org/10.1007/s11030-023-10671-1
8. https://doi.org/10.3390/molecules29061233
9. https://doi.org/10.1056/NEJMoa2214131
10. https://doi.org/10.3390/molecules29061233;
11. https://doi.org/10.1007/s11030-023-10671-1;
12. https://doi.org/10.1021/acs.jcim.4c01392
13. https://doi.org/10.1056/NEJMoa2214131;
14. https://doi.org/10.17877/de290r-24470
15. https://doi.org/10.3390/molecules29061233,
16. https://doi.org/10.1007/s11030-023-10671-1,
17. https://doi.org/10.17877/de290r-24470,
18. https://doi.org/10.1021/acs.jcim.4c01392,